Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 With or Without DLI for Hematological Neoplasms After Stem Cell Transplant
NCT06297629Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inqovi in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and adverse events at 1 year. Planned start Jul 2024; status: withdrawn.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06297629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297629.